共 50 条
- [31] SIMULTANEOUS TARGETING OF THE PD-L1 AND THE TGF-B PATHWAYS WITH BINTRAFUSP ALFA IN EXPERIMENTAL GLIOMASNEURO-ONCOLOGY, 2022, 24 : 137 - 137Silginer, ManuelaWeller, MichaelKienzler, JennyNunez, NicolasLan, YanWeiss, TobiasBecher, BurkhardRoth, Patrick
- [32] PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)NEURO-ONCOLOGY, 2018, 20 : 4 - 4Khasraw, MustafaWeller, MichaelEstelles, David LorenteKolibaba, KathrynLee, CheeGedye, CraigDe La Fuente, MacarenaVicente, DavidReardon, DavidOjalvo, LaureenHelwig, ChristophGourmelon, CaroleGroves, Morris
- [33] Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignanciesCANCER RESEARCH, 2019, 79 (13)Strauss, JuliusGatti-Mays, Margaret E.Cho, ByoungSalas, SebastienMcClay, EdwardRedman, JasonSater, Houssein AbdulDonahue, Renee N.Lamping, ElizabethBurmeister, AndreaMarte, Jennifer L.Cordes, LisaOjalvo, Laureen S.Helwig, ChristophRolfe, AlexHinrichs, Christian S.Madan, Ravi A.Schlom, JeffreyGulley, James
- [34] Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-βSCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (424)Lan, YanZhang, DongXu, ChunxiaoHance, Kenneth W.Marelli, BoQi, JinYu, HuakuiQin, GuozhongSircar, AroopHernandez, Vivian M.Jenkins, Molly H.Fontana, Rachel E.Deshpande, AmitLocke, GeorgeSabzevari, HelenRadvanyi, LaszloLo, Kin-Ming
- [35] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for pretreated advanced cervical cancer: Data from a clinical expansion cohort of a phase I studyANNALS OF ONCOLOGY, 2021, 32 : S753 - S753Feng, J.Wang, J.Tang, D.Zhou, Q.Peng, J.Lou, H.Sun, Y.Cai, Y.Chen, H.Zhang, X.Yang, J.Liu, P.
- [36] Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Strauss, JuliusGatti-Mays, Margaret ElenaRedman, JasonMadan, Ravi AmritLamping, ElizabethManu, MichellBurmeister, AndreaMarte, Jennifer L.Cordes, Lisa M.Ojalvo, LaureenHelwig, ChristophSchlom, JeffreyGulley, James L.
- [37] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Shi, MeiqiChen, JianhuaLi, KunYanFang, YongWen, GuilanLi, XingyaLiu, YunpengSun, YupingZhu, BoLin, LizhuShi, YuankaiWang, LinnaYang, JunqinLiu, PanFeng, Jifeng
- [38] Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β in advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Gulley, James L.Heery, Christopher RyanSchlom, JeffreyMadan, Ravi AmritCao, LiangLambing, ElizabethMarte, Jennifer L.Cordes, Lisa M.Christensen, OlafHelwig, ChristophStrauss, Julius
- [39] Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1ANNALS OF ONCOLOGY, 2018, 29Lin, C-C.Doi, T.Muro, K.Hou, M-M.Esaki, T.Hara, H.Chung, H-C.Osada, M.Helwig, C.Kondo, S.
- [40] Initial results from phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with NSCLC refractory or resistant to prior anti-PD-1/anti-PD-L1 agentsJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5Barlesi, FabriceIsambert, NicolasFelip, EnriquetaCho, Byoung ChulLee, Dae HoPeguero, JulioJerusalem, GuyPenel, NicolasSaada-Bouzid, EsmaGarrido, PilarHelwig, ChristophDussault, IsabelleOjalvo, LaureenGulley, James